Get the Stockscreener App
4.51
4.04%
-0.19
After Hours:
4.51
Y Mabs Therapeutics Inc stock is traded at $4.51, with a volume of 131.17K.
It is down -4.04% in the last 24 hours and down -1.96% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$4.70
Open:
$4.71
24h Volume:
131.17K
Relative Volume:
0.55
Market Cap:
$231.46M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-9.2041
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
-4.45%
1M Performance:
-1.96%
6M Performance:
-42.40%
1Y Performance:
-62.67%
1-Day Range:
$4.48
$4.73
1-Week Range:
$4.48
$5.33
52-Week Range:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
646-885-8505
Address
202 CARNEGIE CENTER, PRINCETON, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.51 | 231.46M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com
Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance
(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World
Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail
How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com
Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus
Y-mAbs Therapeutics (YMAB) Target Price Lowered by Oppenheimer | YMAB Stock News - GuruFocus
Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating - marketscreener.com
Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline - TipRanks
Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Transcript : Y-mAbs Therapeutics, Inc.Special Call - marketscreener.com
Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating - marketscreener.com
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress - TipRanks
Y-mAbs Therapeutics Announces Positive Phase 1 Trial Results for GD2-SADA in Metastatic Solid Tumors and Expands Radiopharmaceutical Pipeline - Nasdaq
Clinical Trial Success: Y-mAbs Breakthrough in Cancer Treatment Shows Promise with Novel Radiopharmaceutical - Stock Titan
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 - MSN
Y-mAbs Therapeutics, Inc. Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - marketscreener.com
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - The Manila Times
Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting - Nasdaq
Y-mAbs Advanced Cancer Trial Breakthrough: Key Data Coming for Revolutionary GD2-SADA Treatment - Stock Titan
Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles - Investing.com Canada
Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles By Investing.com - Investing.com South Africa
What is HC Wainwright’s Forecast for YMAB FY2026 Earnings? - Defense World
HC Wainwright Issues Pessimistic Estimate for YMAB Earnings - Defense World
Caligan Partners LP Increases Stake in Y-mAbs Therapeutics Inc - GuruFocus
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright - Defense World
What 7 Analyst Ratings Have To Say About Y-mAbs Therapeutics - Benzinga
H.C. Wainwright Adjusts Price Target for Y-mAbs Therapeutics (YM - GuruFocus
Price T Rowe Associates Inc. MD Cuts Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
FY2025 EPS Estimates for YMAB Increased by Analyst - Defense World
Formulation Is Key For Y-mAbs' Self-Assembling Antibody - Bioprocess Online
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Oppenheimer Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Q2 EPS Estimates for Y-mAbs Therapeutics Cut by Wedbush - Defense World
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates - MSN
Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook - TipRanks
Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Y-mAbs Therapeutics (YMAB) Maintains "Outperform" Rating, PT Low - GuruFocus
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Y Mabs Therapeutics Inc Stock (YMAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rossi Michael J | PRESIDENT & CEO |
Mar 07 '25 |
Sale |
5.20 |
3,917 |
20,368 |
137,083 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):